Exiqon Licenses miRNA Analysis Technology from Rosetta Inpharmatics

Nov 19, 2007

NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics.

The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.

Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.

Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Skipped Steps

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

Just a Few Bats

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

This Week in Nature

In Nature this week: investigation into the genetics of medulloblastoma, and more.

Genomics for the Trees

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Main menu